Healthcare / Drug Manufacturers - Specialty & GenericParis
$1.37
+0.05 (+3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $14.9M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$130M
P/E
N/A
•EV/EBITDA
8.2x
↓ROE
-26.8%
↓Gross Margin
17.0%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.6%
FCF CAGR
—
FCF margin
5.9%
FCF / Net income
-0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $852.6M · net income $-211.2M · FCF $50.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $852.6M | $852.6M | $919.2M | $1.02B | $980.9M |
| Net Income | $-211.2M | $-211.2M | $-130.6M | $-189.7M | $-15.0M |
| EBITDA | $10.0M | $10.0M | $-42.5M | $70.7M | $101.8M |
| EPS | — | — | -1.38 | -2.02 | -0.16 |
| Gross Margin | 17.0% | 17.0% | 15.5% | 16.2% | 18.0% |
| Operating Margin | 0.2% | 0.2% | -1.1% | 0.4% | 2.8% |
| Net Margin | -24.8% | -24.8% | -14.2% | -18.6% | -1.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.07 | 0.24 | 0.11 |
| Current Ratio | 2.60 | 2.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $50.0M | $50.0M | $14.9M | $-127.7M | $-122.6M |
| Returns | |||||
| ROE | -26.8% | -26.8% | -13.3% | -20.4% | -1.4% |
| Valuation | |||||
| EV/EBITDA | 8.20 | 8.20 | — | 10.32 | 13.59 |
| P/B | 0.17 | 0.17 | 0.28 | 0.58 | 1.20 |
| Growth & Yield | |||||
| Revenue Growth | -7.2% | -7.2% | -9.8% | 3.9% | — |
| EPS Growth | — | — | 31.7% | -1162.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.38 → n/d
Residual
-51.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.